Compare Bristol-Myers Squibb Co (BMY) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Schwab US Large Cap Growth ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.73 (market cap $129.94B), while Schwab US Large Cap Growth ETF trades at $35.62. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Schwab US Large Cap Growth ETF pays none. Which is the better fit depends on your goals.
| BMY | SCHG | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $65.89 | $35.83 |
52-Week Low | $42.60 | $28.10 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
SCHG trades at $35.62, down 0.59% today, with a bullish technical outlook supported by moving averages. The ETF's concentrated portfolio of large-cap growth stocks, particularly in technology, drives performance but introduces concentration risk. Recent news highlights strong historical returns and institutional activity, though some analysts question current valuations.
Outlook remains positive given exposure to AI and technology growth trends, but investors face risks from high concentration in top holdings and sensitivity to interest rate changes. The low 0.04% expense ratio and tax efficiency are key advantages for long-term growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
